JAMA Oncology

Papers
(The H4-Index of JAMA Oncology is 74. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-05-01 to 2025-05-01.)
ArticleCitations
Insights Into Immune-Mediated Disease and Cancer Risk—Delivering on the Promise of UK Biobank Big Data1180
What Is the Optimal Treatment for Vulnerable Older Women With Ovarian Cancer?393
Immunotherapy in Prepatients—Preventing or Promoting a Malignant Transformation?357
Malignant Pericardial Effusion, or Fluid Around the Heart Due to Cancer336
Stereotactic Ablative Body Radiotherapy for Metastases Needs Better Evidence291
Information Blocking and Oncology288
Analysis of Quality-of-Life Outcomes by Drug Class in Cancer Clinical Trials—Reply268
High-risk Medulloblastoma—Balancing the High Stakes of Molecular Profiling to Enhance Treatment Responsivity252
JAMA Oncology239
Active Cellular Immunotherapy in the Desert of Advanced Prostate Cancer232
Induction Chemotherapy for Advanced Nasopharyngeal Carcinoma—Is This the New Standard of Care?231
Redefining Attribution From Patient to Health System—How the Notion of “Mistrust” Places Blame on Black Patients—Reply229
Systemic Anticancer Therapy and Overall Survival in Patients With Very Advanced Solid Tumors221
Radiation-Associated Secondary Cancer in Patients With Breast Cancer Harboring TP53 Germline Variants217
Concerns Regarding the Utility of High-Risk Pancreatic Cancer Surveillance—Reply201
Sexual Rehabilitation Needs of Gay and Bisexual Men With Cancer194
Transplant-Free Approach in Relapsed Hodgkin Lymphoma in Children, Adolescents, and Young Adults191
Stargazers184
Biomarker Analysis of Vistusertib Plus Paclitaxel Regimen177
Methodology Concerns Regarding Claims Data Studies in Transgender Health—Reply174
Errors in Key Points and Abstract171
Error in Text170
Coffee Consumption and Colorectal Cancer Prognosis—Reply168
The 2021 US Preventive Services Task Force Recommendation on Lung Cancer Screening164
Piercing the Fog162
Firearm Safety for Patients Diagnosed With Cancer—A Role in Suicide Prevention157
Radiotherapy to Enhance Chimeric Antigen Receptor T-Cell Therapeutic Efficacy in Solid Tumors155
The Implications of the Supreme Court Decision to Overturn Roe v Wade for Women With Pregnancy-Associated Cancers152
The Multidisciplinary Cancer Conference144
Audit of Data Sharing by Pharmaceutical Companies for Anticancer Medicines Approved by the US Food and Drug Administration139
The Inclusion of Women in Global Oncology Drug Trials Over the Past 20 Years138
Diversity Trends by Sex and Underrepresented in Medicine Status Among US Radiation and Medical Oncology Faculty Over 5 Decades133
Association Between Overall Survival and the Tendency for Cancer Programs to Administer Neoadjuvant Chemotherapy for Patients With Advanced Ovarian Cancer128
Overall Survival in the CAIRO5 Clinical Trial128
Atezolizumab and Platinum Plus Pemetrexed With or Without Bevacizumab for Metastatic Nonsquamous Non–Small Cell Lung Cancer123
Effect of Second-generation vs Third-generation Chemotherapy Regimens With Thoracic Radiotherapy on Unresectable Stage III Non–Small-Cell Lung Cancer123
Long-term Effect of Machine Learning–Triggered Behavioral Nudges on Serious Illness Conversations and End-of-Life Outcomes Among Patients With Cancer121
Association of Modifiable Risk Factors With Early Discontinuation of Adjuvant Endocrine Therapy121
Assessment of a Genomic Assay in Patients With ERBB2-Positive Breast Cancer Following Neoadjuvant Trastuzumab-Based Chemotherapy With or Without Pertuzumab114
Human Leukocyte Antigen Class I Antigen-Processing Machinery Upregulation by Anticancer Therapies in the Era of Checkpoint Inhibitors109
Allogeneic CD19/CD22 CAR T-Cell Therapy for B-Cell Acute Lymphoblastic Leukemia109
The Global Economic Cost of Cancer—Estimating It Is Just the First Step!108
Association of Body Mass Index With the Safety Profile of Nivolumab With or Without Ipilimumab108
Natural Language Processing–Assessed Unmet Medical and Social Needs in Cancer Crowdfunding Stories106
Outcomes Associated With Thiotepa-Based Conditioning in Patients With Primary Central Nervous System Lymphoma After Autologous Hematopoietic Cell Transplant106
SARS-CoV-2 Infections, Hospitalizations, and Mortality in Vaccinated Patients With Cancer in the US101
Project Optimus: Is the US Food and Drug Administration Waiving Dose Optimization for Orphan Drugs?101
The Most Difficult Lesson From Cancer Just Might Be Its Most Valuable101
Use of Participation to Prevalence Ratio for Evaluating the Representation Status of Women in Oncology Clinical Trials—Reply101
Effect of Supine vs Prone Breast Radiotherapy on Acute Toxic Effects of the Skin Among Women With Large Breast Size99
What Is the Optimal Treatment for Vulnerable Older Women With Ovarian Cancer?96
Association of 5α-Reductase Inhibitor Use With Prostate Cancer–Specific Mortality—Reply94
Internal Mammary Nodal Irradiation Debate for Node-Positive Breast Cancer—Has the Needle Moved?—Reply93
Population-Based Prostate Cancer Screening With Magnetic Resonance Imaging or Ultrasonography—The IP1-PROSTAGRAM Study—Reply93
Coding Errors in Study of Eligibility for Lung Cancer Screening91
Is Colorectal Cancer Screening Absolutely Beneficial for Older Adults?91
Is Appendiceal Cancer a Lynch Syndrome–Associated Cancer?91
Asymptomatic Purpuric Eruption on the Scalp of a Middle-aged Man90
Industry Payments to Medical Oncologists89
Errors in Reported Outcomes and Table86
Results of the TARGET-TP Randomized Clinical Trial84
Variability in COVID-19 Vaccine Response Among People With Cancer83
The SOUND Randomized Clinical Trial Results83
The Oncologic Drugs Advisory Committee Votes of April 2021—Implications for the Fate of Accelerated Approval81
Trauma79
Integrated Palliative and Oncology Care for Patients With Acute Myeloid Leukemia—Moving From Evidence to Practice79
JAMA Oncology78
An Atypical Rash on the Chest78
Immunotherapy Before Chemoradiotherapy—More Is Better?77
Assessment of Racial Disparity in Survival Outcomes for Early Hormone Receptor–Positive Breast Cancer After Adjusting for Insurance Status and Neighborhood Deprivation77
BRCA1, BRCA2, and Associated Cancer Risks and Management for Male Patients76
Elotuzumab and Weekly Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Without Transplant Intent76
Anti–Programmed Death Ligand 1 Plus Targeted Therapy in Anaplastic Thyroid Carcinoma75
Noninferiority of Hypofractionated vs Conventional Postprostatectomy Radiotherapy for Genitourinary and Gastrointestinal Symptoms74
Accelerated Approval Is Not Conditional Approval74
3.2619390487671